Bullish indicating open at $55-$60, IPO prices at $37
Investing.com - Mizuho (NYSE:MFG) raised its price target on Embecta (NASDAQ:EMBC) to $14.00 from $12.00 on Monday, while maintaining a Neutral rating on the medical device company’s stock. According to InvestingPro data, the company currently trades at an attractive P/E ratio of 8.64 and offers a dividend yield of 4.89%.
The price target increase follows Embecta’s fiscal third-quarter results, which exceeded expectations with a $17 million revenue beat and $0.34 adjusted earnings per share above consensus. Adjusted EBITDA reached $131 million, significantly outperforming the Street’s expectation of $103 million. InvestingPro analysis indicates the company appears undervalued, with strong financial health metrics and a robust current ratio of 2.47.
Embecta’s strong performance was attributed to robust U.S. sales, combined with effective cost controls and debt reduction. The company benefited from pricing strategies, operational efficiencies, and controlled operating expenses during the quarter.
The company has updated its fiscal year guidance, tightening its constant currency revenue outlook to a decline of 3.0% to 3.6%, compared to the previous range of -2.5% to -4.0%. Embecta also raised its adjusted EPS guidance from $2.70-$2.90 to $2.90-$2.95.
Despite the positive quarter, Mizuho noted that the pull-forward orders driving U.S. outperformance are not expected to continue in the fiscal fourth quarter, while China’s geopolitical landscape presents ongoing headwinds. The firm did highlight potentially positive revenue opportunities from generic GLP-1 pen needles beginning in 2026. With a market capitalization of $718.2 million and impressive free cash flow yield, InvestingPro subscribers can access 8 additional key insights about Embecta’s investment potential through the comprehensive Pro Research Report.
In other recent news, Embecta Corp reported impressive financial results for Q3 2025, exceeding analyst expectations. The company achieved earnings per share of $1.12, significantly surpassing the forecasted $0.77, representing a 45.45% surprise. Additionally, Embecta’s revenue reached $295.5 million, outperforming the anticipated $278.15 million. These results highlight a strong performance for the company in the third quarter. Following this announcement, analysts and investors have taken note of Embecta’s robust financial health. The positive earnings report has drawn attention from various analyst firms, although specific upgrades or downgrades were not mentioned. These developments reflect recent progress and achievements for Embecta Corp.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.